tiprankstipranks
Trending News
More News >
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
US Market
Advertisement

Crinetics Pharmaceuticals (CRNX) Stock Forecast & Price Target

Compare
621 Followers
See the Price Targets and Ratings of:

CRNX Analyst Ratings

Strong Buy
16Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Crinetics
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CRNX Stock 12 Month Forecast

Average Price Target

$77.47
▲(115.85% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Crinetics Pharmaceuticals in the last 3 months. The average price target is $77.47 with a high forecast of $143.00 and a low forecast of $40.00. The average price target represents a 115.85% change from the last price of $35.89.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","85":"$85","144":"$144","55.5":"$55.5","114.5":"$114.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,55.5,85,114.5,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.3,41.738461538461536,50.176923076923075,58.61538461538461,67.05384615384615,75.49230769230769,83.93076923076923,92.36923076923077,100.8076923076923,109.24615384615385,117.68461538461538,126.12307692307692,134.56153846153848,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.3,36.69769230769231,40.09538461538461,43.49307692307692,46.89076923076923,50.28846153846153,53.68615384615384,57.08384615384615,60.48153846153846,63.879230769230766,67.27692307692308,70.67461538461538,74.07230769230769,{"y":77.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.3,33.815384615384616,34.33076923076923,34.84615384615385,35.36153846153846,35.87692307692308,36.39230769230769,36.90769230769231,37.42307692307692,37.93846153846154,38.45384615384615,38.96923076923077,39.48461538461538,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.69,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.13,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.3,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.84,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$143.00Average Price Target$77.47Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRNX
H.C. Wainwright
H.C. Wainwright
$81
Buy
125.69%
Upside
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)
Citizens JMP Analyst forecast on CRNX
Citizens JMP
Citizens JMP
$86$143
Buy
298.44%
Upside
Reiterated
09/26/25
Crinetics price target raised to $143 from $86 at Citizens JMPCrinetics price target raised to $143 from $86 at Citizens JMP
Piper Sandler Analyst forecast on CRNX
Piper Sandler
Piper Sandler
$97
Buy
170.27%
Upside
Reiterated
09/26/25
Piper Sandler Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)
JonesTrading Analyst forecast on CRNX
JonesTrading
JonesTrading
$65$85
Buy
136.83%
Upside
Reiterated
09/26/25
Crinetics Pharmaceuticals (CRNX) Gets a Buy from JonesTradingJones Trading analyst Catherine Novack raised the price target on Crinetics (NASDAQ: CRNX) to $85.00 (from $65.00) while maintaining a Buy rating.
Morgan Stanley Analyst forecast on CRNX
Morgan Stanley
Morgan Stanley
$65$77
Buy
114.54%
Upside
Reiterated
09/26/25
Morgan Stanley Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Morgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $77.00 (from $65.00) while maintaining a Overweight rating.
LifeSci Capital Analyst forecast on CRNX
LifeSci Capital
LifeSci Capital
$82$92
Buy
156.34%
Upside
Reiterated
09/26/25
Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of PalsonifyDriven by updated guidance on pricing (we initially modeled an annual WAC of $100k with dose-based pricing) and refined TAM, we are increasing our pricetarget from $82 to $92/sh.
Goldman Sachs Analyst forecast on CRNX
Goldman Sachs
Goldman Sachs
$35$40
Hold
11.45%
Upside
Reiterated
09/26/25
Goldman Sachs Reaffirms Their Hold Rating on Crinetics Pharmaceuticals (CRNX)
Stifel Nicolaus Analyst forecast on CRNX
Stifel Nicolaus
Stifel Nicolaus
$58
Buy
61.60%
Upside
Reiterated
09/26/25
Stifel Nicolaus Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)
Oppenheimer Analyst forecast on CRNX
Oppenheimer
Oppenheimer
$73
Buy
103.40%
Upside
Reiterated
09/26/25
Oppenheimer Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
Robert W. Baird Analyst forecast on CRNX
Robert W. Baird
Robert W. Baird
$58$62
Buy
72.75%
Upside
Reiterated
09/26/25
Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Baird analyst Brian Skorney raised the price target on Crinetics (NASDAQ: CRNX) to $62.00 (from $58.00) while maintaining a Outperform rating.
J.P. Morgan Analyst forecast on CRNX
J.P. Morgan
J.P. Morgan
$53$52
Buy
44.89%
Upside
Reiterated
09/24/25
Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan
Leerink Partners Analyst forecast on CRNX
Leerink Partners
Leerink Partners
$80
Buy
122.90%
Upside
Reiterated
09/23/25
Analysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)
Cantor Fitzgerald Analyst forecast on CRNX
Cantor Fitzgerald
Cantor Fitzgerald
$90
Buy
150.77%
Upside
Initiated
09/22/25
Crinetics Pharmaceuticals (CRNX) Initiated with a Buy at Cantor Fitzgerald
Evercore ISI Analyst forecast on CRNX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$72
Buy
100.61%
Upside
Reiterated
08/11/25
Crinetics Pharmaceuticals (CRNX) Receives a Buy from Evercore ISIEarnings Overload SMID Biotech Week in Review
Citi
$63$60
Buy
67.18%
Upside
Reiterated
08/08/25
Crinetics Pharmaceuticals (CRNX) Receives a Buy from Citi
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CRNX
H.C. Wainwright
H.C. Wainwright
$81
Buy
125.69%
Upside
Reiterated
09/26/25
Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Crinetics Pharmaceuticals (CRNX)
Citizens JMP Analyst forecast on CRNX
Citizens JMP
Citizens JMP
$86$143
Buy
298.44%
Upside
Reiterated
09/26/25
Crinetics price target raised to $143 from $86 at Citizens JMPCrinetics price target raised to $143 from $86 at Citizens JMP
Piper Sandler Analyst forecast on CRNX
Piper Sandler
Piper Sandler
$97
Buy
170.27%
Upside
Reiterated
09/26/25
Piper Sandler Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)
JonesTrading Analyst forecast on CRNX
JonesTrading
JonesTrading
$65$85
Buy
136.83%
Upside
Reiterated
09/26/25
Crinetics Pharmaceuticals (CRNX) Gets a Buy from JonesTradingJones Trading analyst Catherine Novack raised the price target on Crinetics (NASDAQ: CRNX) to $85.00 (from $65.00) while maintaining a Buy rating.
Morgan Stanley Analyst forecast on CRNX
Morgan Stanley
Morgan Stanley
$65$77
Buy
114.54%
Upside
Reiterated
09/26/25
Morgan Stanley Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Morgan Stanley analyst Jeffrey Hung raised the price target on Crinetics (NASDAQ: CRNX) to $77.00 (from $65.00) while maintaining a Overweight rating.
LifeSci Capital Analyst forecast on CRNX
LifeSci Capital
LifeSci Capital
$82$92
Buy
156.34%
Upside
Reiterated
09/26/25
Buy Rating for Crinetics Pharmaceuticals Driven by FDA Approval and Strategic Market Positioning of PalsonifyDriven by updated guidance on pricing (we initially modeled an annual WAC of $100k with dose-based pricing) and refined TAM, we are increasing our pricetarget from $82 to $92/sh.
Goldman Sachs Analyst forecast on CRNX
Goldman Sachs
Goldman Sachs
$35$40
Hold
11.45%
Upside
Reiterated
09/26/25
Goldman Sachs Reaffirms Their Hold Rating on Crinetics Pharmaceuticals (CRNX)
Stifel Nicolaus Analyst forecast on CRNX
Stifel Nicolaus
Stifel Nicolaus
$58
Buy
61.60%
Upside
Reiterated
09/26/25
Stifel Nicolaus Sticks to Their Buy Rating for Crinetics Pharmaceuticals (CRNX)
Oppenheimer Analyst forecast on CRNX
Oppenheimer
Oppenheimer
$73
Buy
103.40%
Upside
Reiterated
09/26/25
Oppenheimer Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
Robert W. Baird Analyst forecast on CRNX
Robert W. Baird
Robert W. Baird
$58$62
Buy
72.75%
Upside
Reiterated
09/26/25
Robert W. Baird Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)Baird analyst Brian Skorney raised the price target on Crinetics (NASDAQ: CRNX) to $62.00 (from $58.00) while maintaining a Outperform rating.
J.P. Morgan Analyst forecast on CRNX
J.P. Morgan
J.P. Morgan
$53$52
Buy
44.89%
Upside
Reiterated
09/24/25
Crinetics price target lowered to $52 from $53 at JPMorganCrinetics price target lowered to $52 from $53 at JPMorgan
Leerink Partners Analyst forecast on CRNX
Leerink Partners
Leerink Partners
$80
Buy
122.90%
Upside
Reiterated
09/23/25
Analysts Are Bullish on Top Healthcare Stocks: Avidity Biosciences (RNA), Crinetics Pharmaceuticals (CRNX)
Cantor Fitzgerald Analyst forecast on CRNX
Cantor Fitzgerald
Cantor Fitzgerald
$90
Buy
150.77%
Upside
Initiated
09/22/25
Crinetics Pharmaceuticals (CRNX) Initiated with a Buy at Cantor Fitzgerald
Evercore ISI Analyst forecast on CRNX
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$72
Buy
100.61%
Upside
Reiterated
08/11/25
Crinetics Pharmaceuticals (CRNX) Receives a Buy from Evercore ISIEarnings Overload SMID Biotech Week in Review
Citi
$63$60
Buy
67.18%
Upside
Reiterated
08/08/25
Crinetics Pharmaceuticals (CRNX) Receives a Buy from Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crinetics Pharmaceuticals

1 Month
xxx
Success Rate
8/13 ratings generated profit
62%
Average Return
+10.10%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 61.54% of your transactions generating a profit, with an average return of +10.10% per trade.
3 Months
xxx
Success Rate
10/13 ratings generated profit
77%
Average Return
+20.54%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +20.54% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
14/22 ratings generated profit
64%
Average Return
+34.12%
reiterated a buy rating yesterday
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +34.12% per trade.
2 Years
xxx
Success Rate
21/31 ratings generated profit
68%
Average Return
+58.22%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 67.74% of your transactions generating a profit, with an average return of +58.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CRNX Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
14
17
22
25
28
Buy
1
1
1
1
4
Hold
7
9
10
8
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
27
33
34
38
In the current month, CRNX has received 32 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. CRNX average Analyst price target in the past 3 months is 77.47.
Each month's total comprises the sum of three months' worth of ratings.

CRNX Financial Forecast

CRNX Earnings Forecast

Next quarter’s earnings estimate for CRNX is -$1.25 with a range of -$1.44 to -$1.00. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.
Next quarter’s earnings estimate for CRNX is -$1.25 with a range of -$1.44 to -$1.00. The previous quarter’s EPS was -$1.23. CRNX beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.16% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.

CRNX Sales Forecast

Next quarter’s sales forecast for CRNX is $430.00K with a range of $0.00 to $2.70M. The previous quarter’s sales results were $1.03M. CRNX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.
Next quarter’s sales forecast for CRNX is $430.00K with a range of $0.00 to $2.70M. The previous quarter’s sales results were $1.03M. CRNX beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.12% of the time in the same period. In the last calendar year CRNX has Outperformed its overall industry.

CRNX Stock Forecast FAQ

What is CRNX’s average 12-month price target, according to analysts?
Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is 77.47.
    What is CRNX’s upside potential, based on the analysts’ average price target?
    Crinetics Pharmaceuticals has 115.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CRNX a Buy, Sell or Hold?
          Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Crinetics Pharmaceuticals’s price target?
            The average price target for Crinetics Pharmaceuticals is 77.47. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $143.00 ,the lowest forecast is $40.00. The average price target represents 115.85% Increase from the current price of $35.89.
              What do analysts say about Crinetics Pharmaceuticals?
              Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of CRNX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis